BIOCARTIS news, videos and press releases - Page 5
For more news please use our advanced search feature.
BIOCARTIS - More news...
BIOCARTIS - More news...
- Biocartis Group NV: Disclosure of outstanding voting securities
- Biocartis Group NV: Genomic Health and Biocartis Expand Collaboration to Urology with the Development of an Idylla(TM) Oncotype DX Genomic Prostate Score® Test
- Biocartis Group NV: Biocartis and AstraZeneca Enter Into Agreement Aimed at Faster Lung Cancer Biomarker Results
- Biocartis Group NV: BIOCARTIS Q3 2018 BUSINESS UPDATE
- Biocartis Group NV: Eight Idylla(TM) Performance Studies to be Presented at the Association for Molecular Pathology Conference in the US
- Biocartis Group NV: Shareholding Disclosure
- Biocartis Group NV: Disclosure of a transparency notification
- Biocartis Group NV: Disclosure of a transparency notification
- Biocartis Group NV: Studies on Idylla(TM) MSI and RAS liquid biopsy tests to be presented at ESMO congress
- Biocartis Group NV: DISCLOSURE OF OUTSTANDING VOTING SECURITIES
- Biocartis Group NV: Disclosure of a transparency notification
- Biocartis Group NV: Biocartis Creates New Warrant Plan
- Biocartis Group NV: BIOCARTIS ANNOUNCES H1 2018 RESULTS
- Biocartis Group NV: BIOCARTIS ANNOUNCES H1 2018 RESULTS
- Biocartis Group NV: Biocartis and Wondfo Announce Joint Venture for Commercialization of Idylla(TM) Platform in China
- Biocartis Group NV: Biocartis announces 2018 half-year results on 6 September 2018
- Biocartis Group NV: Biocartis Obtains Exclusive Worldwide License Rights for EGFR Ectodomain Mutations Determining Response to Targeted Colorectal Cancer Therapy
- Biocartis Group NV: Study Abstract on Performance of Idylla(TM) RAS tests Selected for Oral Presentation at 70th AACC Annual Scientific Meeting in Chicago, IL (US)
- Biocartis Group NV: Biocartis launches innovative Idylla(TM) MSI Assay
- Biocartis Group NV: Study Reviewing 2,500 Performed Idylla(TM) Tests Shows Generation of Valid Results in 98.1% of Cases and Outperformance over Reference Methods
- Biocartis Group NV: Disclosure of a transparency notification
- Biocartis Group NV: Study Demonstrates Ability of Idylla(TM) EGFR Mutation Test to Produce a Result in 80% of Failed Next Generation Sequencing Lung Cancer Tests
- Biocartis Group NV: Two Performance Studies on Idylla(TM) MSI Biomarkers Selected for Publication at ASCO Conference
- Biocartis Group NV: Results of the annual shareholders' meeting held on 11 May 2018
- Biocartis Group NV: BIOCARTIS Q1 2018 BUSINESS UPDATE
- Biocartis Group NV: BIOCARTIS Q1 2018 BUSINESS UPDATE
- Biocartis Group NV: Invitation to Annual Shareholders' Meeting
- Biocartis Group NV: Disclosure of outstanding voting securities
- Biocartis Group NV: Biocartis announces publication of its 2017 annual report
- Biocartis Abstract on Performance Idylla(TM) ctRAS Liquid Biopsy Tests Selected for Oral Presentation at 2018 American Association for Cancer Research Meeting
